Nevro acquired Vyrsa Technologis, a company focused on sacroiliac joint fusion, according to a Nov. 30 news release.
Vyrsa Technologies has an array of SI joint devices and was founded in 2021. It's the only SI joint company with a complete portfolio of FDA-cleared sacroiliac joint fusion implants.
The deal was completed Nov. 30 and values Vyrsa at $40 million. Nevro will also pay up to an additional $35 million pending development and sales milestones.